Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor 60 mg twice daily versus prasugrel 5 mg pharmacodynamic crossover study in post-myocardial infarction patients
2016-004959-80Phase 4Completed
- Sponsor
- National and Kapodistrian University of Athens
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of ticagrelor and prasugrel in myocardial infarction (MI) (2 arms), sponsored by National and Kapodistrian University of Athens. Primary endpoint: Platelet reactivity units. Started Jun 2017; status: completed.
02
Drugs
ticagrelorprasugrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2016-004959-80.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004959-80.